Polhumin Mix-5, 100 IU/ml, suspension for injection
Human insulin
Polhumin Mix-5 is human insulin used to treat diabetes. This insulin is produced using genetic engineering techniques (DNA recombination) in Escherichia colibacteria. It is identical to the insulin produced by the human body.
Insulin is a hormone produced in the human body by the pancreas. It is involved in carbohydrate, fat, and protein metabolism, causing, among other things, a decrease in blood glucose levels.
The cause of diabetes is the pancreas's inability to produce insulin in quantities that allow blood glucose levels to be controlled.
Polhumin Mix-5 is a medium-acting insulin. This means that the onset of action, which reduces blood sugar levels, occurs about 30 minutes after injection, the maximum effect occurs after 2-8 hours, and the total duration of action is up to 24 hours.
The medicine is available in a 3 ml cartridge and is intended for use with an injector.
Warning!Other products must not be added to insulin cartridges. Insulins must not be administered with other medicines in the same syringe.
and overall activity level should be planned carefully. Blood sugar levels should also be monitored frequently.
Some people who have changed from animal insulin to human insulin and have experienced hypoglycemia (low blood sugar levels) have reported that the symptoms warning of hypoglycemia were less pronounced or different from before. If hypoglycemia occurs frequently or there are difficulties in recognizing the symptoms of hypoglycemia, consult a doctor.
Polhumin Mix-5 in cartridges is intended for subcutaneous injection only using a reusable injector. If it is necessary to administer insulin by a different method, consult a doctor.
Skin changes at the injection site
The injection site should be changed to prevent skin changes, such as lumps under the skin. Insulin injected into an area with lumps may not work properly (see "How to use Polhumin Mix-5"). If insulin is currently being injected into an area with lumps, the doctor should be consulted before changing the site. The doctor may recommend more frequent blood sugar monitoring and adjustment of the insulin dose or other anti-diabetic medicines.
The doctor will recommend the appropriate dosage to achieve proper blood sugar levels (normoglycemia) according to the patient's physiological needs.
Tell your doctor about all medicines you are currently taking or have recently taken
and about medicines you plan to take.
It is essential to inform the doctor about taking insulin, especially if you are seeing them for a reason other than diabetes.
The body's need for insulin may change when taking such medicines as:
Medicines that enhance the effect of insulin:
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor or pharmacist before using this medicine.
In women with diabetes, during the childbearing period, it is essential to strive for proper blood sugar levels during insulin treatment.
Insulin does not pass through the placenta into the fetus's blood.
The need for insulin decreases in the first trimester of pregnancy and increases in the next two trimesters. In the final stage of pregnancy, the need for insulin is about twice as high compared to the period before pregnancy.
The need for insulin decreases when labor starts and after delivery (the insulin dose is similar to that used in non-pregnant women with diabetes).
Insulin does not pass into breast milk. Patients treated with insulin can breastfeed. Often, a change in insulin dose or diet is necessary.
Be aware of the possible symptoms of hypoglycemia. The ability to concentrate and react is usually impaired during hypoglycemia. Never drive a vehicle if symptoms indicate impending hypoglycemia. Consult a doctor to carefully consider the possibility of driving a vehicle or operating machines in case of frequent episodes of hypoglycemia or difficulties in recognizing its symptoms.
The medicine contains less than 1 mmol (23 mg) of sodium per dose unit, which means the medicine is considered "sodium-free".
This medicine should always be used according to the doctor's recommendations. In case of doubts, consult a doctor.
The insulin dosage is individual for each patient. The insulin dose is determined based on the patient's age, physical activity, health status (e.g., presence of kidney failure), as well as the use of other medicines. The exact dose of insulin should be determined based on regular monitoring of blood sugar levels and urine tests.
During each change of insulin: e.g., from mixed (porcine-bovine) or bovine insulin to human insulin, change of form, as well as change of manufacturer, a change in dosage may be necessary, which should be done under medical supervision.
In patients who have been well-controlled on highly purified porcine or human insulin, no other dosage changes are expected than those that are routine and aimed at maintaining stable control of the patient's condition.
It is essential to follow the doctor's recommended control visit schedule.
During treatment, regular monitoring of blood sugar levels or urine tests is necessary.
Polhumin Mix-5 in a filled injector is intended for subcutaneous injection only. If it is necessary to administer insulin by a different method, consult a doctor.
Subcutaneous injection should be performed in the abdominal area, buttocks, thigh, or upper arm.
The injection sites should be changed to avoid thickening.
Preparing the insulin in cartridges
Before inserting the cartridge containing insulin into the injector, the cartridge should be turned upside down and back several times, so the glass ball can move freely from one end of the cartridge to the other. This action should be performed several times (about 10 times) until a uniform, cloudy, or milky suspension is obtained. If the cartridge is already in the injector, it should be turned several times as described above.
These actions should be performed before each insulin injection.
Performing the injection
In case of taking a higher dose of the medicine than recommended, consult a doctor immediately.
As a result of insulin overdose, hypoglycemia may occur (causes and symptoms of hypoglycemia - see section 2 "Important information before using Polhumin Mix-5").
The procedure for insulin overdose depends on the severity of hypoglycemia:
In case of missing a dose of insulin, consult a doctor.
In case of missing a dose of the medicine, hyperglycemia may occur.
Do not take a double dose to make up for the missed dose.
In case of missing a dose of the medicine at a fixed, specified time, the medicine should be taken as soon as possible, if the time to the next dose is long enough, or the next dose should be taken at the right time and regular administration of the medicine should be continued.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
As with other insulins, hypoglycemia is the most common complication of insulin therapy.
Side effects reported often(in less than 1 in 10 patients)
Local allergic reaction - symptoms at the injection site (redness, swelling, itching, pain, and bruising at the injection site) may occur during insulin treatment. Most of these symptoms are usually transient and disappear during treatment.
Skin changes at the injection site
If insulin is injected into the same site too frequently, the fatty tissue may shrink (lipoatrophy) or thicken (lipohipertrophy) (not very common - less than 1 in 100 patients). Lumps under the skin can also be caused by the accumulation of a protein called amyloid (cutaneous amyloidosis, frequency of occurrence unknown). Insulin injected into an area with lumps may not work properly. The injection site should be changed every time - this will help prevent these skin changes.
Side effects reported very rarely(in less than 1 in 10,000 patients)
Generalized allergic reaction - may manifest as: generalized skin rash, itching, sweating, gastrointestinal disorders, angioedema, breathing difficulties, palpitations, decreased blood pressure, and fainting/loss of consciousness.
➢ If such symptoms occur during the use of Polhumin Mix-5, consult a doctor immediately.
If side effects occur, including any not listed in this leaflet, tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C, 02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of the medicine.
Keep out of sight and reach of children.
Store in a refrigerator (2°C – 8°C).
Do not freeze.
Store in the original packaging to protect from light.
After opening, the cartridge can be stored for a maximum of 28 days at a temperature below 25°C.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Do not use this medicine if you notice a change in the appearance of the packaging contents.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance of the medicine is biosynthetic highly purified human insulin.
1 ml of the suspension contains 100 IU of human insulin.
One cartridge for the injector contains 3 ml of the suspension, which corresponds to 300 IU of biphasic insulin in a ratio of 5 parts of soluble insulin and 5 parts of isophane insulin.
Other ingredients of the medicine are protamine sulfate, disodium phosphate dodecahydrate, phenol, metacresol, glycerol, zinc chloride (4% solution), hydrochloric acid (0.1 mol/l solution), sodium hydroxide (0.1 mol/l solution), and water for injections.
White or almost white, neutral, sterile, aqueous suspension of human insulin in a cartridge.
5 cartridges of 3 ml each in a PVC/Aluminum blister pack, in a cardboard box.
The cartridges are glass cylinders made of neutral, colorless glass, internally siliconized on both sides, closed with a rubber stopper and an aluminum cap with a rubber disk, made of a bromobutyl mixture. Each cartridge contains 2 glass balls.
Tarchomińskie Zakłady Farmaceutyczne "Polfa" Spółka Akcyjna
ul. A. Fleminga 2
03-176 Warsaw
Phone number: 22 811-18-14
To obtain more detailed information, contact the representative of the marketing authorization holder.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.